A multi-centre performance evaluation of a commercially developed liquid biopsy for the earlier detection of brain tumours
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Dec 2025 · 1 min read
In brief
In brief
The EMBRACE study evaluated a commercial liquid biopsy platform across 2,554 patients in Europe for earlier brain tumor detection in primary care settings. The test achieved 86% sensitivity for malignant brain cancers with 99% NPV, potentially enabling more efficient triage of patients with non-specific neurological symptoms before emergency presentation.
Written by the GCMD Library team from the article.
Statements in this article
Two-thirds of brain cancer patients receive their diagnosis only after presenting to the emergency department with more severe symptoms or neurological deficits.
The EMBRACE study prospectively recruited patients across seven sites in Europe from the United Kingdom, Belgium, Sweden and Switzerland.
The target population consisted of patients with symptoms potentially associated with brain cancer.
Test performance was assessed by comparison of the liquid biopsy result to diagnostic imaging.
2554 patients were enrolled across the seven collection sites, with 2324 deemed eligible for test assessment.
There were 697 brain tumours in total, of which 395 were malignant, and 1627 non-tumour diagnoses.
The Dxcover® Brain Cancer Liquid Biopsy Platform demonstrated 86% sensitivity for brain cancer detection.
The Dxcover® Brain Cancer Liquid Biopsy Platform demonstrated 99% negative predictive value for brain cancer detection.
Sensitivity for all brain tumours combined (malignant and benign) was 77%.